Kazuya Takeda

Dr. Kazuya Takeda

Tohoku University, Sendai, Miyagi, Japan
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2017 in Journal of Radiation Research
Verified
Journal Article
Open access
PDF file
KTKazuya Takeda
Kazuya Takeda
KTKentaro Takanami
Kentaro Takanami
YSYuko Shirata
Yuko Shirata
TYTakaya Yamamoto
Takaya Yamamoto
NTNoriyoshi Takahashi
Noriyoshi Takahashi
KJKeiichi Jingu
Keiichi Jingu
We evaluated the reproducibility and predictive value of texture parameters and existing parameters of 18F-FDG PET/CT images in Stage I non-small-cell lung cancer (NSCLC) patients treated with stereotactic body radiotherapy (SBRT). Twenty-six patients with Stage I NSCLC (T1-2N0M0) were retrospectively analyzed. All of the patients underwent an 18F-FDG PET/CT scan before treatment and were treated with SBRT. Each tumor was delineated using PET Edge (MIM Software Inc., Cleveland, OH), and texture parameters were calculated using open-source code CGITA. From 18F-FDG PET/CT images, three conventional parameters, including maximum standardized uptake value (SUV), metabolic tumor volume (MTV) and total lesion glycolysis (TLG), and four texture parameters, including entropy and dissimilarity (derived from a co-occurrence matrix) and high-intensity large-area emphasis (HILAE) and zone percentage (derived from a size-zone matrix) were analyzed. Reproducibility was evaluated using two independent delineations conducted by two observers. The ability to predict local control (LC), progression-free survival (PFS) and overall survival (OS) was tested for each parameter. All of the seven parameters except zone percentage showed good reproducibility, with intraclass correlation coefficient values >0.8. In univariate analysis, only HILAE was a significant predictor for LC. Histology, dose fractionation, and maximum SUV were associated with PFS, and histology and dose fractionation were associated with OS. We showed that texture parameters derived from 18F-FDG PET/CT were reproducible and potentially beneficial for predicting LC in Stage I lung cancer patients treated with SBRT.

12 April 2022 in BMC Palliative Care
Verified
Journal Article
Open access
PDF file
KTKazuya Takeda
Kazuya Takeda
TSToru Sakayauchi
Toru Sakayauchi
MKMasaki Kubozono
Masaki Kubozono
YKYu Katagiri
Yu Katagiri
RURei Umezawa
Rei Umezawa
KJKeiichi Jingu
Keiichi Jingu
Background: Palliative radiotherapy for gastric cancer bleeding has been reported to be a safe and effective treatment, but predictive factors for achievement of hemostasis and overall survival have not been established. Methods: In this retrospective study, 120 courses of palliative radiotherapy for gastric cancer bleeding in 117 patients in 4 institutes in Japan were reviewed with approval of the ethical committee in each institute. The rate of achieving hemostasis was evaluated by 50% or more reduction of red blood cell transfusion before and after the start of radiotherapy, elevation of blood hemoglobin concentration in a period of 4 weeks from the start of radiotherapy or improvement of subjective or objective clinical symptoms in a period of 4 weeks from the start of radiotherapy. Predictive factors for overall survival and achieving hemostasis were investigated with the Cox hazards model. Results: The median overall survival period was 3.7 months. Multivariate analysis showed that absence of metastatic disease, higher biological effective dose, higher serum albumin level, lower blood urea nitrogen level and lower neutrophil-to-lymphocyte ratio (NLR) were associated with longer overall survival. Elevation of hemoglobin concentration in a period of 4 weeks from the start of radiotherapy (mean concentration: 8.2 g/dL vs. 8.9 g/dL, p = 0.006) and decrease in the amount of red cell transfusion from a 4-week period before to a 4-week period after the start of radiotherapy (mean amount: 716 mL vs. 230 mL, p < 0.0001) were observed. The overall rate of achievement of hemostasis was 59.6%. In multivariate analysis, higher biological effective dose was associated with achievement of hemostasis. Grade 2 or higher acute adverse effects related to radiotherapy were observed in 17.5% of cases in 120 treatment courses. Six cases (5.0%) had grade 3 or 4 adverse effects including gastric penetration in 1 patient and anorexia requiring total parental nutrition in 3 patients. No grade 5 adverse effects were observed. Conclusions: Palliative radiotherapy for gastric cancer bleeding seems to be an effective and safe treatment strategy. Higher treatment dose was associated with longer overall survival and a hemostatic effect. Some hematological parameters may predict overall survival, and they would be helpful for deciding the treatment strategy.

26 March 2018 in Esophagus
Verified
Journal Article
Closed access
PDF file
KTKazuya Takeda
Kazuya Takeda
RURei Umezawa
Rei Umezawa
NTNoriyoshi Takahashi
Noriyoshi Takahashi
HMHaruo Matsushita
Haruo Matsushita
MKMaiko Kozumi
Maiko Kozumi
KJKeiichi Jingu
Keiichi Jingu

22 September 2023 in Journal of Radiation Research
Verified
Journal Article
Open access
PDF file
KTKazuya Takeda
Kazuya Takeda
RURei Umezawa
Rei Umezawa
TYTakaya Yamamoto
Takaya Yamamoto
NTNoriyoshi Takahashi
Noriyoshi Takahashi
YSYu Suzuki
Yu Suzuki
KJKeiichi Jingu
Keiichi Jingu
To investigate radiation-induced cytopenia and establish predictive nomograms for hematological toxicity, we reviewed 3786 patients aged 18 or older who received radiation monotherapy between 2010 and 2021 for non-hematologic malignancies. We collected data on patient background, treatment content and hematologic toxicities for 12 weeks after the start of radiotherapy. The patients were randomly divided into training and test groups in 7:3 ratio. In the training group, we conducted ordered logistic regression analysis to identify predictive factors for neutropenia, lymphocytopenia, anemia and thrombocytopenia. Nomograms to predict Grade 2–4 cytopenia were generated and validated in the test group. Grade 3 or higher hematologic toxicities were observed in 9.7, 44.6, 8.3 and 3.1% of patients with neutropenia, lymphocytopenia, anemia and thrombocytopenia, respectively. We identified six factors for neutropenia grade, nine for lymphocytopenia grade and six for anemia grade with statistical significance. In the analysis of thrombocytopenia, the statistical model did not converge because of a small number of events. Nomograms were generated using factors with high predictive power. In evaluating the nomograms, we found high area under the receiver operating characteristic curve values (neutropenia; 0.75–0.85, lymphopenia; 0.89–0.91 and anemia; 0.85–0.86) in predicting Grade 2–4 cytopenia in the test group. We established predictive nomograms for neutropenia, leukocytopenia and anemia and demonstrated high reproducibility when validated in an independent cohort of patients.

29 February 2024 in Precision Radiation Oncology
Verified
Journal Article
Open access
KTKazuya Takeda
Kazuya Takeda
RURei Umezawa
Rei Umezawa
TYTakaya Yamamoto
Takaya Yamamoto
NTNoriyoshi Takahashi
Noriyoshi Takahashi
YSYu Suzuki
Yu Suzuki
KJKeiichi Jingu
Keiichi Jingu
Objective: We retrospectively analyzed breast cancer patients who received adjuvant radiotherapy to determine the incidence of lymphocytopenia and its risk factors.Methods: We reviewed 812 patients with breast cancer who received postoperative radiotherapy. Patients were divided into two groups based on the use of chemotherapy, and a generalized linear regression model was used to explore predictive factors for grade 2 or higher lymphocytopenia. We also examined the effect of lymphocytopenia on overall survival.Results: Grade 2 or higher lymphocytopenia was observed in 19.4% of patients who did not receive chemotherapy and 45.1% of patients who received chemotherapy. In multivariate analysis, bilateral disease, regional lymph node irradiation, and baseline lymphocytopenia were associated with lymphocytopenia in patients who did not receive cytotoxic chemotherapy. Regional lymph node irradiation, baseline lymphocytopenia, use of antimetabolites, and use of molecular‐targeted agents were associated with lymphocytopenia in patients treated with chemotherapy. In the survival analysis, lymphocytopenia was associated with worse overall survival only in patients treated with cytotoxic chemotherapy (p = 0.039), and not in patients who did not receive chemotherapy (p = 0.77).Conclusion: The analysis revealed the incidence and risk factors of lymphocytopenia after postoperative radiotherapy in patients with breast cancer.

1 January 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SSSoichiro Shiga
Soichiro Shiga
YMYasuhiko Murata
Yasuhiko Murata
THTakuma Hashimoto
Takuma Hashimoto
YUYusuke Urushihara
Yusuke Urushihara
YFYohei Fujishima
Yohei Fujishima
YHYoshio Hosoi
Yoshio Hosoi